DE60003011D1 - Modulierung der gefässepermeabilität mittels tie2 rezeptoraktivatoren - Google Patents

Modulierung der gefässepermeabilität mittels tie2 rezeptoraktivatoren

Info

Publication number
DE60003011D1
DE60003011D1 DE60003011T DE60003011T DE60003011D1 DE 60003011 D1 DE60003011 D1 DE 60003011D1 DE 60003011 T DE60003011 T DE 60003011T DE 60003011 T DE60003011 T DE 60003011T DE 60003011 D1 DE60003011 D1 DE 60003011D1
Authority
DE
Germany
Prior art keywords
vascer
permability
modulating
tie2 receptor
receptor activators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60003011T
Other languages
English (en)
Other versions
DE60003011T2 (de
Inventor
Chitra Suri
D Yancopoulos
Gavin Thurston
Donald Mcdonald
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Regeneron Pharmaceuticals Inc
Original Assignee
University of California
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/286,033 external-priority patent/US6455035B1/en
Application filed by University of California, Regeneron Pharmaceuticals Inc filed Critical University of California
Application granted granted Critical
Publication of DE60003011D1 publication Critical patent/DE60003011D1/de
Publication of DE60003011T2 publication Critical patent/DE60003011T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE60003011T 1999-03-26 2000-03-20 Modulierung der gefässepermeabilität mittels tie2 rezeptoraktivatoren Expired - Lifetime DE60003011T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12653999P 1999-03-26 1999-03-26
US126539P 1999-03-26
US286033 1999-04-05
US09/286,033 US6455035B1 (en) 1999-03-26 1999-04-05 Angiopoietins and methods of use thereof
PCT/US2000/007336 WO2000057901A1 (en) 1999-03-26 2000-03-20 Modulation of vascular permeability by means of tie2 receptor activators

Publications (2)

Publication Number Publication Date
DE60003011D1 true DE60003011D1 (de) 2003-07-03
DE60003011T2 DE60003011T2 (de) 2004-04-08

Family

ID=26824785

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60003011T Expired - Lifetime DE60003011T2 (de) 1999-03-26 2000-03-20 Modulierung der gefässepermeabilität mittels tie2 rezeptoraktivatoren

Country Status (14)

Country Link
EP (1) EP1165115B1 (de)
JP (1) JP2002540165A (de)
AT (1) ATE241380T1 (de)
AU (1) AU769198B2 (de)
CA (1) CA2368670C (de)
DE (1) DE60003011T2 (de)
DK (1) DK1165115T3 (de)
ES (1) ES2199804T3 (de)
HK (1) HK1043537A1 (de)
IL (2) IL145504A0 (de)
NO (1) NO329198B1 (de)
NZ (1) NZ514434A (de)
PT (1) PT1165115E (de)
WO (1) WO2000057901A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6753321B2 (en) 2000-09-15 2004-06-22 Genvec, Inc. Method of modulating neovascularization
US7138370B2 (en) * 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
AU2006228095B2 (en) * 2001-10-11 2010-11-04 Amgen Inc. Angiopoietin-2 specific binding agents
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
RU2404992C2 (ru) * 2004-10-19 2010-11-27 Эмджен Инк. Ангиопоэтин-2-специфические связывающие агенты
PL1838733T3 (pl) 2004-12-21 2012-02-29 Medimmune Ltd Przeciwciała skierowane przeciwko angiopoetynie-2 i ich zastosowania
JP5179373B2 (ja) * 2005-12-15 2013-04-10 アストラゼネカ アクチボラグ 癌を治療するためのアンジオポエチン−２アンタゴニストとＶＥＧＦ−Ａ、ＫＤＲ、及び／又はＦｌｔ１アンタゴニストの組合せ
EP2371865B1 (de) 2006-04-07 2017-07-12 Aerpio Therapeutics, Inc. An die humane Proteintyrosinphosphatase-beta (HPTP-ß) bindende Antikörper und Anwendungen davon
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US8507656B2 (en) 2008-01-28 2013-08-13 Medimmune Limited Stabilized angiopoietin-2 antibodies and uses thereof
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
TR201809280T4 (tr) * 2009-01-12 2018-07-23 Aerpio Therapeutics Inc Vasküler sızıntı sendromunun tedavi edilmesine yönelik yöntemler.
AU2016203254B2 (en) * 2009-01-12 2018-09-13 EyePoint Pharmaceuticals, Inc. Methods for treating vascular leak syndrome
RU2519123C2 (ru) 2009-07-06 2014-06-10 Аэрпио Терапьютикс Инк. Соединения, композиции и способы предупреждения метастазов раковых клеток
EP3505182A1 (de) 2011-10-13 2019-07-03 Aerpio Therapeutics, Inc. Verfahren zur behandlung von kapillarlecksyndrom und krebs
ES2774972T3 (es) 2011-10-13 2020-07-23 Aerpio Therapeutics Inc Tratamiento de enfermedades oculares
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
EP2832746B1 (de) 2013-07-29 2018-07-18 Samsung Electronics Co., Ltd Anti-ANG2-Antikörper
KR102196450B1 (ko) 2013-09-17 2020-12-30 삼성전자주식회사 Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제
US9994560B2 (en) 2014-03-14 2018-06-12 Aerpio Therapeutics, Inc. HPTP-β inhibitors
CN113713101B (zh) 2015-09-23 2023-07-28 视点制药公司 用tie-2的激活剂治疗眼内压的方法
BR112019001206A2 (pt) 2016-07-20 2019-06-25 Aerpio Therapeutics Inc anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss)
CN114269341A (zh) 2019-04-29 2022-04-01 视点制药公司 靶向施莱姆管的Tie-2激活剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6277318A (ja) * 1985-10-01 1987-04-09 Eisai Co Ltd 熱傷治療剤
US5482930A (en) * 1993-06-09 1996-01-09 The Regents Of The University Of California Anti-inflammatory composition and method with des-Tyr dynorphin and analogues
ATE306546T1 (de) * 1996-08-23 2005-10-15 Ludwig Inst Cancer Res Rekombinanter vaskulärer endothelzellen wachstumsfaktor d (vegf-d)
US6365154B1 (en) * 1998-09-28 2002-04-02 Smithkline Beecham Corporation Tie2 agonist antibodies

Also Published As

Publication number Publication date
CA2368670C (en) 2012-06-05
DE60003011T2 (de) 2004-04-08
DK1165115T3 (da) 2003-09-22
ES2199804T3 (es) 2004-03-01
NO329198B1 (no) 2010-09-13
AU3763400A (en) 2000-10-16
HK1043537A1 (zh) 2002-09-20
IL145504A (en) 2008-08-07
EP1165115B1 (de) 2003-05-28
JP2002540165A (ja) 2002-11-26
NZ514434A (en) 2003-11-28
IL145504A0 (en) 2002-06-30
EP1165115A1 (de) 2002-01-02
CA2368670A1 (en) 2000-10-05
NO20014673L (no) 2001-11-22
WO2000057901A1 (en) 2000-10-05
AU769198B2 (en) 2004-01-22
PT1165115E (pt) 2003-10-31
ATE241380T1 (de) 2003-06-15
NO20014673D0 (no) 2001-09-26

Similar Documents

Publication Publication Date Title
DE60003011D1 (de) Modulierung der gefässepermeabilität mittels tie2 rezeptoraktivatoren
BR0108396A (pt) Derivados de pirimidina-4-0na como inibidores de ldl-pla(2)
TR200200843T2 (tr) İşemi'nin Tedavisi için olan bileşikler
NO20025590D0 (no) Fenylglycin-derivater
TR200000782T2 (tr) Resorsinol türevleri.
MXPA03002477A (es) N-acilsulfonamidas promotras de la apoptosis.
NO20030374D0 (no) Syklopentanoindoler, preparater som inneholder slike forbindelser og behandlingsfremgangsmåter
ATE211931T1 (de) Topoisomerase inhibitoren zur restenose- prevention
DE69919700D1 (de) Überbrückte indenopyrrolocarbazole
TR200103094T2 (tr) ACE-2 inhibe eden bileçikler ve bunlarìn kullanìm y”ntemi
PL1668001T3 (pl) Podstawione heteroarylobenzofuranowe kwasy
ES2216630T3 (es) Metodos de tratar la hipertension dependiente de la sal.
DE60105025D1 (de) Pharmazeutische verbindungen zur behandlung von chronisch-obstruktiver bronchopneumonie
AP2001002274A0 (en) Rescorcinol derivatives.
MXPA02012470A (es) Inhibidores de fosfodiesterasa especificos para gmp ciclico.
TR200102514T2 (tr) COPD tedavisi için metod
EA199901043A1 (ru) ИНГИБИТОРЫ ФАРНЕЗИЛТРАНСФЕРАЗЫ В КОМБИНАЦИИ С ИНГИБИТОРАМИ HMG-CoA-РЕДУКТАЗЫ ДЛЯ ЛЕЧЕНИЯ РАКА
DE60122559D1 (de) Indolderivate als pde5-inhibitoren
ATE293111T1 (de) Kondensierte pyrazindionderivate als pde inhibitoren
NO20026078D0 (no) Farmasöytiske preparater innbefattende akryloyl distamycinderivater og topoisomerase I- og II-inhibitorer
DE50109698D1 (de) N-heteroarylmethyl-m-phenylendiamin-derivate enthaltende färbemittel für keratinfasern sowie neue n-heteroarylmethyl-m-phenylendiamin-derivate
PT1156999E (pt) Metodo para a preparacao de um beta-aminoester quiral
DE60219788D1 (de) Tetrazyklische verbindungen als pde5-inhibitoren
ATE270113T1 (de) Zusammenstellungen zur verbesserten wundheilung
NZ331678A (en) Method of checking integrity of modified atmosphere package by placing gas indicator between package and liner

Legal Events

Date Code Title Description
8364 No opposition during term of opposition